Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
April 18th 2016

Are Oncology Clinical Pathways a Value Framework in the Making?

Surabhi Dangi-Garimella, PhD
Evidence-Based Oncology invited a panel of experts who are experienced in the creation of oncology care pathways, use them in their practice, and have researched the development and implementation of care pathways, to exchange ideas on the topic.
Site Logo
April 18th 2016

Targeting Stem Cells in Multiple Myeloma Could Improve Outcomes

Surabhi Dangi-Garimella, PhD
Targeting cancer stem cells could have a much better impact on the outcome of patients with multiple myeloma being treated with standard chemotherapy, a new single-arm study by researchers at Johns Hopkins has found.
This Week in Managed Care: April 16, 2016
April 16th 2016

This Week in Managed Care: April 16, 2016

The top stories in managed care include a recap of Patient-Centered Diabetes Care, the case for the Oncology Medical Home, UnitedHealth leaves Affordable Care Act exchanges in 2 states, and CMS expands alternative payment model for primary care.
Site Logo
April 16th 2016

Clinical Pathways: A Systems Approach Toward More Patient-Centric Cancer Care Delivery

Joseph Alvarnas, MD
Despite the fundamental advances in cancer care technology and care delivery that have made these improvements possible, our delivery system remains quite inefficient and frequently falls short of being truly patient-centered. Is a system-based solution the answer?
Dr Lucio Gordan Highlights Challenges Facing Oncologists in 2016
April 15th 2016

Dr Lucio Gordan Highlights Challenges Facing Oncologists in 2016

The biggest challenge facing oncologists in 2016 is the Medicare Part B demonstration that CMS announced, Lucio Gordan, MD, of Florida Cancer Specialists, said at the Community Oncology Alliance's 2016 Community Oncology Conference.
Site Logo
April 15th 2016

Industry Insight on the Challenges With Developing and Adopting Biosimilars

Surabhi Dangi-Garimella, PhD
Pharmaceutical industry experts provide an overview of the highly complex biosimilar development process at The Community Oncology Conference: Innovation in Cancer Care, held in Orlando, Florida.
Site Logo
April 15th 2016

Developing an Oncology Clinical Pathways Program - the UPMC Case Study

Peter G. Ellis, MD
An overview of the oncology clinical pathways development program at the UPMC CancerCenter and how it led to the creation of Via Oncology, a clinical pathways vendor.
Site Logo
April 15th 2016

Oncology Payment Reform: Payers and Providers Discuss APM and Beyond

Surabhi Dangi-Garimella, PhD
Everyone in healthcare is currently grappling with what payment reform will look like in the coming years, and oncology is no exception. Payers, providers, and health policy experts reviewed ongoing changes in the healthcare system and shared their vision on what the future would look like.
Dr Alan Balch on Improving Shared Decision-Making in Cancer Care
April 14th 2016

Dr Alan Balch on Improving Shared Decision-Making in Cancer Care

Patients and providers often have very different views of goals and values when it comes to treatment, so healthcare could benefit from figuring out how to systematize the shared decision making experience, Alan Balch, PhD, chief executive officer of the National Patient Advocate Foundation, said at the Community Oncology Alliance's 2016 Community Oncology Conference.
Site Logo
April 14th 2016

An Update on the Oncology Medical Home Model at the COA Conference

Surabhi Dangi-Garimella, PhD
Representatives from 3 clinics that successfully participated in the Commission on Cancer accreditation process for the Oncology Medical Home model participated in a panel discussion on the first day of The Community Oncology Conference: Innovation in Cancer Care.
Dr Debra Patt Outlines Cancer Care Delivery, Payment Changes
April 14th 2016

Dr Debra Patt Outlines Cancer Care Delivery, Payment Changes

There are a number of models that look at innovating payments and focus on care delivery changes in oncology that are a positive step forward for patients, Debra Patt, MD, MPH, MBA, director of public policy at Texas Oncology, said at the Community Oncology Alliance's 2016 Community Oncology Conference.
Site Logo
April 14th 2016

Aligning Reimbursement With Quality: Are We There Yet?

Surabhi Dangi-Garimella, PhD
On the first day of The Community Oncology Conference: Innovation in Cancer Care, held in Orlando, Florida, April 13-15, 2016, oncologists discussed how their practices are coping with the transition toward quality- and value-based reimbursement.
Dr Stephen Grubbs Discusses Creating ASCO's Value Framework
April 14th 2016

Dr Stephen Grubbs Discusses Creating ASCO's Value Framework

Many value assessment frameworks are still in their infancy and while the American Society of Clinical Oncology (ASCO)'s framework is still getting input and being adjusted, it has started an important conversation, Stephen Grubbs, MD, vice president for clinical affairs at ASCO, said at the Community Oncology Alliance's 2016 Community Oncology Conference.
Site Logo
April 13th 2016

ODAC Advises FDA to Wait for Results of TIGER-3 for Rociletinib in NSCLC

Surabhi Dangi-Garimella, PhD
The committee voted 12-1 in favor of delaying approval of the drug and waiting on results from the phase 3 study.
Site Logo
April 13th 2016

Striking the Balance in Prostate Cancer: Active Surveillance Versus Disease Progression

Surabhi Dangi-Garimella, PhD
A new study published in The Journal of Urology has found that active surveillance in prostate cancer patients who might have a low-grade disease has the possibility of disease progression in only a small number of patients.
Site Logo
April 12th 2016

Benefit of Aspirin to Prevent CVD and CRC Upheld by USPSTF

Surabhi Dangi-Garimella, PhD
An updated recommendation by the US Preventive Services Task Force advises the use of low-dose aspirin in adults 50 to 69 years of age, who have an increased risk of cardiovascular disease (CVD) or colorectal cancer (CRC), are not at an increased risk of bleeding, and have a life expectancy of at least 10 years, for the prevention of CVD and CRC.
Site Logo
April 11th 2016

BCL-2 Inhibitor Venetoclax Approved as Second Line for CLL With 17p Deletion

Surabhi Dangi-Garimella, PhD
The approval comes following the review of a phase 2 single-arm trial in 106 patients with chronic lymphocytic leukemia who carried the 17p deletion mutation and who had received at least 1 prior therapy for their condition.
Site Logo
April 11th 2016

Race and Source of Information Influence Cancer Patient's Estimate of Life Expectancy

Surabhi Dangi-Garimella, PhD
A prospective longitudinal study that followed terminally ill cancer patients till their death has found that patients of African American origins had a poorer understanding of their survival than the white patients in the study group.
Site Logo
April 8th 2016

Are FDA Reviewers Concerned About the Value of Clovis Oncology's EGFR Inhibitor Rociletinib?

AJMC Staff
A preliminary briefing document expresses concerns over clinical benefit over existing treatments, safety, and overall risk-benefit of the drug for the subset of lung cancer patients for whom the drug has been developed.
Site Logo
April 8th 2016

5 Takeaways From the NCCN Annual Conference

Surabhi Dangi-Garimella, PhD
The National Comprehensive Cancer Network (NCCN)'s annual conference has traditionally been a platform for NCCN’s Guideline updates. This year's meeting saw much more, with discussions on palliative care, biosimilars, and value in cancer care.
Site Logo
April 7th 2016

ICER to Evaluate Value of Amgen's Multiple Myeloma Treatment

Surabhi Dangi-Garimella, PhD
Drug developer Amgen is questioning the assessment of its multiple myeloma treatments at the hands of the Institute for Clinical and Economic Review.
Site Logo
April 7th 2016

Chemotherapy With Radiation Can Improve Outcomes in Glioma Patients

Surabhi Dangi-Garimella, PhD
Patients with grade 2 glial brain tumors (gliomas) who were treated with radiation therapy (RT) and chemotherapy had a longer progression-free survival and overall survival than those who received RT alone.
Site Logo
April 6th 2016

Hypofractionated Radiotherapy Could Improve QoL and Be Cost-Effective in Prostate Cancer

Surabhi Dangi-Garimella, PhD
In men with low-risk prostate cancer, hypofractionation is non-inferior than the standard treatment dose and has the potential for saving treatment costs, according to a new study in the Journal of Clinical Oncology.
Site Logo
April 5th 2016

Physician Bias in Shared Decision Making - Can It Be Resolved?

Surabhi Dangi-Garimella, PhD
Site Logo
April 5th 2016

FDA's Califf Tells Fellow Cardiologists How Precision Medicine Can Reshape Clinical Trials

Mary Caffrey
The nation's top food and drug regulator enjoyed a warm welcome from colleagues on the final day of the 65th Scientific Session of the American College of Cardiology.
Site Logo
April 5th 2016

Cancer Care Has Not Overtaken Overall Healthcare Costs, Clarifies Milliman Study

Surabhi Dangi-Garimella, PhD
The study, commissioned by the Community Oncology Alliance, has found that overall costs for Medicare and commercial health plan enrollees have been increasing at the same rate as the cost of treating patients with cancer. This contradicts the popular notion that cancer care costs have far outpaced overall healthcare spending.
Site Logo
April 5th 2016

The Promise of Cancer Immunotherapy: Why Patient Education Is Critical, Part II

Debra Madden
It is imperative that we gather more mature data on a much larger number of patients to accurately assess efficacy, safety, potential harms, durability of response, and impact on disease progression and overall survival of the new immunotherapy treatments.
Site Logo
April 4th 2016

Successful Intervention Improved Breast Cancer Screening Rates Among Latinos

Surabhi Dangi-Garimella, PhD
A new study by researchers at the Kaiser Permanente Center for Health Research has found that visits by trained community health workers improved screening rates for breast cancer among Latino women.
Site Logo
April 2nd 2016

The Politics of Cancer Care in 2016

Surabhi Dangi-Garimella, PhD
Four panelists and 2 moderators discussed the issues surrounding cancer and healthcare in the lead-up to the 2016 presidential election during the National Comprehensive Cancer Network 21st Annual Conference.
Dr John Thompson Outlines Updates in Melanoma
April 2nd 2016

Dr John Thompson Outlines Updates in Melanoma

John A. Thompson, MD, co-director of the Melanoma Clinic at the Seattle Cancer Care Alliance, highlighted the major points of his melanoma talk at the National Comprehensive Cancer Network’s 21st Annual Meeting, including the FDA approval of new drugs and the development of new viral therapies.
<1
...
105106107108109110111112113
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo